Tempus Announces Research Collaboration with Bristol Myers Squibb to Apply Multimodal AI Approaches
Tempus (NYSE: TMPS) announces strategic research collaboration with Bristol Myers Squibb to accelerate cancer research and treatment options using AI, multimodal datasets, and patient-derived disease models.
Positive
Strategic collaboration with a major pharmaceutical company like Bristol Myers Squibb indicates Tempus' growing influence and recognition in the precision medicine industry.
The collaboration aims to identify new drug targets and validate them faster and with higher confidence, potentially leading to innovative therapies and improved patient outcomes.
11/08/2023 - 09:00 AM
CHICAGO --(BUSINESS WIRE)--
Tempus, a leader in artificial intelligence and precision medicine, today announced a multi-year, strategic research collaboration with Bristol Myers Squibb (NYSE: BMY). The two companies will work together to identify new targets and validate them faster and with higher confidence using multimodal datasets, computational approaches, and patient-derived disease models in specific cancer disease areas.
"We are looking forward to expanding our relationship with Bristol Myers Squibb and furthering our shared commitment to advancing cancer research and treatment options for patients that need it most,” said Ryan Fukushima, Chief Operating Officer at Tempus. “By combining the power of Tempus’ multimodal data, biological modeling, and machine learning approaches with Bristol Myers Squibb’s discovery expertise and research and development capabilities, we can accelerate discoveries, innovate therapies, and improve the lives of patients battling cancer.”
The Tempus and Bristol Myers Squibb teams will focus their initial research on identifying new drug targets to expand options for patients lacking effective therapies, or who have become refractory to existing treatment. Teams from both companies will work in a highly collaborative manner to jointly analyze disease cohorts within Tempus’ large multimodal database and apply systems biology approaches to uncover novel targets that can be quickly and iteratively tested using Tempus’ library of patient-derived organoids.
About Tempus
Tempus is a technology company advancing precision medicine through the practical application of artificial intelligence in healthcare. With one of the world’s largest libraries of multimodal data, and an operating system to make that data accessible and useful, Tempus provides AI-enabled precision medicine solutions to physicians to deliver personalized patient care and in parallel facilitates discovery, development and delivery of optimal therapeutics. The goal is for each patient to benefit from the treatment of others who came before by providing physicians with tools that learn as the company gathers more data. For more information, visit tempus.com .
View source version on businesswire.com: https://www.businesswire.com/news/home/20231108309609/en/
Erin Carron
communications@tempus.com
Source: Tempus
What is the nature of the collaboration between Tempus and Bristol Myers Squibb?
The collaboration aims to identify new drug targets and validate them using AI, multimodal datasets, and patient-derived disease models to accelerate cancer research and treatment options.
Who is the Chief Operating Officer at Tempus?
Ryan Fukushima is the Chief Operating Officer at Tempus.
What is the focus of the initial research between the two companies?
The initial research will focus on identifying new drug targets to expand options for patients lacking effective therapies or who have become refractory to existing treatment.
How will the teams from Tempus and Bristol Myers Squibb work together?
The teams will work collaboratively to analyze disease cohorts within Tempus' large multimodal database and apply systems biology approaches to uncover novel targets that can be quickly and iteratively tested using patient-derived organoids from Tempus' library.
